An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement Disorders.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
19 Mar 2024
19 Mar 2024
Historique:
accepted:
27
02
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
aheadofprint
Résumé
Drug-induced movement disorders (DIMDs) are associated with use of dopamine receptor blocking agents (DRBAs), including antipsychotics. The most common forms are drug-induced parkinsonism (DIP), dystonia, akathisia, and tardive dyskinesia (TD). Although rare, neuroleptic malignant syndrome (NMS) is a potentially life-threatening consequence of DRBA exposure. Recommendations for anticholinergic use in patients with DIMDs were developed on the basis of a roundtable discussion with healthcare professionals with extensive expertise in DIMD management, along with a comprehensive literature review. The roundtable agreed that "extrapyramidal symptoms" is a non-specific term that encompasses a range of abnormal movements. As such, it contributes to a misconception that all DIMDs can be treated in the same way, potentially leading to the misuse and overprescribing of anticholinergics. DIMDs are neurobiologically and clinically distinct, with different treatment paradigms and varying levels of evidence for anticholinergic use. Whereas evidence indicates anticholinergics can be effective for DIP and dystonia, they are not recommended for TD, akathisia, or NMS; nor are they supported for preventing DIMDs except in individuals at high risk for acute dystonia. Anticholinergics may induce serious peripheral adverse effects (e.g., urinary retention) and central effects (e.g., impaired cognition), all of which can be highly concerning especially in older adults. Appropriate use of anticholinergics therefore requires careful consideration of the evidence for efficacy (e.g., supportive for DIP but not TD) and the risks for serious adverse events. If used, anticholinergic medications should be prescribed at the lowest effective dose and for limited periods of time. When discontinued, they should be tapered gradually.
Identifiants
pubmed: 38502289
doi: 10.1007/s40263-024-01078-z
pii: 10.1007/s40263-024-01078-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Stagnitti MN. Trends in antipsychotics purchases and expenses for the U.S. civilian noninstitutionalized population, 1997 and 2007. Statistical Brief #275. Agency for Healthcare Research and Quality, Rockville, MD. 2010.
Ahrnsbra R, Stagnitti MN. Comparision of antidepressant and antipsychotic utilization and expenditures in the U.S. civilian noninstitutionalized population, 2013 and 2018. Statistical Brief #534. Agency for Healthcare Research and Quality, Rockville, MD. 2021.
Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18–28.
pubmed: 22534420
pmcid: 3382997
doi: 10.1016/j.schres.2012.03.018
Dilks S, Xavier RM, Kelly C, Johnson J. Implications of antipsychotic use: antipsychotic-induced movement disorders, with a focus on tardive dyskinesia. Nurs Clin N Am. 2019;54:595–608.
doi: 10.1016/j.cnur.2019.08.004
Muhlbauer V, Mohler R, Dichter MN, Zuidema SU, Kopke S, Luijendijk HJ. Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2021;12:CD013304.
pubmed: 34918337
Devanand DP. Management of neuropsychiatric symptoms in dementia. Curr Opin Neurol. 2023;36:498–503.
pubmed: 37639488
doi: 10.1097/WCO.0000000000001199
Iversen TSJ, Steen NE, Dieset I, Hope S, Mørch R, Gardsjord ES, et al. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:263–71.
pubmed: 29122637
doi: 10.1016/j.pnpbp.2017.11.004
Meyer JM, Correll CU. Increased metabolic potential, efficacy, and safety of emerging treatments in schizophrenia. CNS Drugs. 2023;37:545–70.
pubmed: 37470979
pmcid: 10374807
doi: 10.1007/s40263-023-01022-7
Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM, et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022;27:208–17.
pubmed: 33213556
doi: 10.1017/S109285292000200X
Chepke C, Benning B, Cicero S, Hull M, Giraldo E, Yeaw J, et al. Investigating real-world benztropine usage patterns in movement disorders: claims analysis and health care provider survey results. Prim Care Companion CNS Disord. 2023;25:22m03472.
Schatzberg AF, Nemeroff CB, American Psychiatric Association. The American Psychiatric Association Publishing textbook of psychopharmacology. 5th ed. Arlington: American Psychiatric Association Publishing; 2017.
doi: 10.1176/appi.books.9781615371624
Yohn SE, Weiden PJ, Felder CC, Stahl SM. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43:1098–112.
pubmed: 36273943
doi: 10.1016/j.tips.2022.09.006
Ho TNT, Abraham N, Lewis RJ. Structure-function of neuronal nicotinic acetylcholine receptor inhibitors derived from natural toxins. Front Neurosci. 2020;14: 609005.
pubmed: 33324158
pmcid: 7723979
doi: 10.3389/fnins.2020.609005
Brocks DR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2:39–46.
pubmed: 10952768
Lester DB, Rogers TD, Blaha CD. Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther. 2010;16:137–62.
pubmed: 20370804
pmcid: 6493877
doi: 10.1111/j.1755-5949.2010.00142.x
Ztaou S, Amalric M. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson’s disease. Neurochem Int. 2019;126:1–10.
pubmed: 30825602
doi: 10.1016/j.neuint.2019.02.019
Paz RM, Murer MG. Mechanisms of antiparkinsonian anticholinergic therapy revisited. Neuroscience. 2021;467:201–17.
pubmed: 34048797
doi: 10.1016/j.neuroscience.2021.05.026
Ward KM, Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia - Key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233–48.
pubmed: 30027457
pmcid: 6283785
doi: 10.1007/s40120-018-0105-0
Kharkwal G, Brami-Cherrier K, Lizardi-Ortiz JE, Nelson AB, Ramos M, Del Barrio D, et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron. 2016;91:67–78.
pubmed: 27387649
pmcid: 4939839
doi: 10.1016/j.neuron.2016.06.014
Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Ther Adv Psychopharmacol. 2022;12:20451253221117310.
pubmed: 36312846
pmcid: 9597038
doi: 10.1177/20451253221117313
Loonen AJ, Ivanova SA. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 2013;18:15–20.
pubmed: 23593652
doi: 10.1017/S1092852912000752
Bergman H, Soares-Weiser K. Anticholinergic medication for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:Cd000204.
pubmed: 29341071
Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA, et al. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81:463–9.
pubmed: 23897874
doi: 10.1212/WNL.0b013e31829d86b6
Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry. 1974;37:941–7.
pubmed: 4418481
pmcid: 494809
doi: 10.1136/jnnp.37.8.941
Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry. 1984;145:304–10.
pubmed: 6148119
doi: 10.1192/bjp.145.3.304
Yassa R. Tardive dyskinesia and anticholinergic drugs. A critical review of the literature. L’Encephale. 1988;14 Spec No:233–9.
pubmed: 3063514
Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23:583–609.
pubmed: 9365997
doi: 10.1093/schbul/23.4.583
Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016;15:753–68.
pubmed: 26966981
doi: 10.1517/14740338.2016.1165664
Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8:1181–8.
pubmed: 34765683
pmcid: 8564829
doi: 10.1002/mdc3.13347
Caroff SN, Campbell EC. Drug-induced extrapyramidal syndromes: implications for contemporary practice. Psychiatric Clin North Am. 2016;39:391–411.
doi: 10.1016/j.psc.2016.04.003
Caroff SN, Jain R, Morley JF. Revisiting amantadine as a treatment for drug-induced movement disorders. Ann Clin Psychiatry. 2020;32:198–208.
pubmed: 32722730
Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, et al. 2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD. Chest. 2023;164:1159–83.
pubmed: 37690008
doi: 10.1016/j.chest.2023.08.014
Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;6:CD012066.
pubmed: 37276335
Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019;30:1603–17.
pubmed: 31346670
pmcid: 6795617
doi: 10.1007/s00192-019-04022-8
Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, et al. Choosing the most efficacious and safe orl teatment for iiopathic oeractive badder: a systematic review and network meta-analysis. Eur Urol Focus. 2022;8:1072–89.
pubmed: 34563481
doi: 10.1016/j.euf.2021.08.011
Gerretsen P, Pollock BG. Drugs with anticholinergic properties: a current perspective on use and safety. Expert Opin Drug Saf. 2011;10:751–65.
pubmed: 21635190
doi: 10.1517/14740338.2011.579899
Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384:717–26.
pubmed: 33626254
pmcid: 7610870
doi: 10.1056/NEJMoa2017015
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022;400:2210–20.
pubmed: 36528376
doi: 10.1016/S0140-6736(22)01990-0
Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. 5th ed. Cambridge: Cambridge University Press; 2021.
doi: 10.1017/9781108975292
Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81:516–24.
pubmed: 26589572
doi: 10.1111/bcp.12839
Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clin Toxicol (Phila). 2021;59:698–704.
pubmed: 33295809
doi: 10.1080/15563650.2020.1854281
Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(Suppl 21):11–4.
pubmed: 11584981
Georgiou R, Lamnisos D, Giannakou K. Anticholinergic burden and cognitive performance in patients with schizophrenia: a systematic literature review. Front Psychiatry. 2021;12: 779607.
pubmed: 35027893
pmcid: 8748260
doi: 10.3389/fpsyt.2021.779607
Kim SJ, Jung D, Shim JC, Moon JJ, Jeon DW, Kim YN, et al. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia. Asian J Psychiatr. 2019;46:111–7.
pubmed: 31654923
doi: 10.1016/j.ajp.2019.10.013
Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009;166:1055–62.
pubmed: 19570929
pmcid: 3735363
doi: 10.1176/appi.ajp.2009.09010017
Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73:721–32.
pubmed: 27088965
pmcid: 5029278
doi: 10.1001/jamaneurol.2016.0580
The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 3rd ed. Washington, DC: American Psychiatric Association; 2021.
Osmolex ER (amantadine) extended-release tablets. Prescribing information. Emeryville, CA: Adamas Pharma, LLC; 2021.
Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69:1869–79.
pubmed: 19192477
pmcid: 4041731
doi: 10.4088/JCP.v69n1204
Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry. 2007;68:1876–85.
pubmed: 18162018
doi: 10.4088/JCP.v68n1207
Citrome L, Risinger R, Rajachandran L, Robison H. Sublingual dexmedetomidine for agitation associated with schizophrenia or bipolar disorder: a post hoc analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Adv Ther. 2022;39:4821–35.
pubmed: 36002761
pmcid: 9464744
doi: 10.1007/s12325-022-02274-3
Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32:1335–46.
pubmed: 6128697
doi: 10.1212/WNL.32.12.1335
Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain. 1998;121:2053–66.
pubmed: 9827766
doi: 10.1093/brain/121.11.2053
Adityanjee, Aderibigbe YA, Jampala VC, Mathews T. The current status of tardive dystonia. Biol Psychiatry. 1999;45:715–30.
pubmed: 10188001
doi: 10.1016/S0006-3223(98)00242-X
Grabel M, Merola A. Pallidal deep brain stimulation for tardive dystonia: meta-analysis of clinical outcomes. Neurol Sci. 2023;44:827–33.
pubmed: 36378365
doi: 10.1007/s10072-022-06506-w
Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15:789–98.
pubmed: 27928948
pmcid: 5771055
doi: 10.2174/1570159X14666161208153644
Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006:CD003727.
Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22:73–81.
pubmed: 10647977
doi: 10.2165/00002018-200022010-00006
Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4:157–75.
pubmed: 2567492
doi: 10.1002/mds.870040208
Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975;16:43–7.
pubmed: 234073
doi: 10.1016/0010-440X(75)90019-X
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text revision. Washington, DC: American Psychiatric Association Publishing; 2022.
doi: 10.1176/appi.books.9780890425787
Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY). 2013;3:tre-03-161-4138-1.
Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectr. 2022;28:4–14.
Caroff SN, Citrome L, Meyer J, Sajatovic M, Goldberg JF, Jain R, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81:19cs12983.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67–75.
pubmed: 29454493
doi: 10.1016/j.jns.2018.02.010
Caroff SN. Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785–94.
pubmed: 31040678
pmcid: 6459148
doi: 10.2147/NDT.S196541
Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6:134–44.
pubmed: 23006238
doi: 10.3371/CSRP.6.3.5
Joshi YB, Thomas ML, Braff DL, Green MF, Gur RC, Gur RE, et al. Anticholinergic medication burden-associated cognitive impairment in schizophrenia. Am J Psychiatry. 2021;178:838–47.
pubmed: 33985348
pmcid: 8440496
doi: 10.1176/appi.ajp.2020.20081212
Trihexyphenidyl hydrochloride tablets. Prescribing information. Kothur-509 228, AP India: Natco Pharma Ltd; 2010.
Benztropine tablets. Prescribing information. Livonia: Major Pharmaceuticals; 2017.
Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454–61.
pubmed: 28404690
doi: 10.1124/jpet.116.239160
INGREZZA® (valbenazine) capsules. Prescribing information. San Diego: Neurocrine Biosciences, Inc.; 2023.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–84.
pubmed: 28320223
doi: 10.1176/appi.ajp.2017.16091037
Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, et al. A phase 3, 1-year, open-label trial of valbenazine in adults with tardive dyskinesia. J Clin Psychopharmacol. 2019;39:620–7.
pubmed: 31688452
doi: 10.1097/JCP.0000000000001111
Austedo (deutetrabenazine) tablets and Austedo XR (deutetrabenazine) extended-release tablets. Prescribing information. Parsippany: Teva Pharmaceuticals USA, Inc.; 2023.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojarvi J, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604.
pubmed: 28668671
doi: 10.1016/S2215-0366(17)30236-5
Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–10.
pubmed: 28446646
pmcid: 5440239
doi: 10.1212/WNL.0000000000003960
Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019;90:1317–23.
pubmed: 31296586
Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57:512–8.
pubmed: 22854034
doi: 10.1177/070674371205700810
Caroff SN, Mann SC, Sullivan KA, Campbell EC. Neuroleptic malignant syndrome. In: Frucht SJ, editor. Movement disorder emergencies: diagnosis and treatment. 3rd ed. Cham: Humana Press; 2022.
Caroff SN, Mann SC, Campbell EC. Risk of fatal heatstroke after hospitalization. Psychiatr Serv. 2000;51:938-a.
doi: 10.1176/appi.ps.51.7.938-a
Davariashtiyani A, Taherkhani M, Fattahpour S, Vitousek S. Exponential increases in high-temperature extremes in North America. Sci Rep. 2023;13:19177.
pubmed: 37932278
pmcid: 10628173
doi: 10.1038/s41598-023-41347-3
Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. A consensus statement. World Health Organization heads of centres collaborating in WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry. 1990;156:412.
Desmarais JE, Beauclair L, Margolese HC. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol (Oxford, England). 2012;26:1167–74.
doi: 10.1177/0269881112447988
Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology. 1979;61:261–2.
pubmed: 36644
doi: 10.1007/BF00432269
Winslow RS, Stillner V, Coons DJ, Robison MW. Prevention of acute dystonic reactions in patients beginning high-potency neuroleptics. Am J Psychiatry. 1986;143:706–10.
pubmed: 2872822
Boyer WF, Bakalar NH, Lake CR. Anticholinergic prophylaxis of acute haloperidol-induced acute dystonic reactions. J Clin Psychopharmacol. 1987;7:164–6.
pubmed: 3597801
doi: 10.1097/00004714-198706000-00008
Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.
pubmed: 17101747
doi: 10.1177/0091270006292126
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.
pubmed: 18332297
doi: 10.1001/archinternmed.2007.106
Ali S, Peterson GM, Bereznicki LR, Salahudeen MS. Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2020;76:319–35.
pubmed: 31832732
doi: 10.1007/s00228-019-02795-x
Graves-Morris K, Stewart C, Soiza RL, Taylor-Rowan M, Quinn TJ, Loke YK, et al. The prognostic value of anticholinergic burden measures in relation to mortality in older individuals: a systematic review and meta-analysis. Front Pharmacol. 2020;11:570.
pubmed: 32411001
pmcid: 7201087
doi: 10.3389/fphar.2020.00570
Mehdizadeh D, Hale M, Todd O, Zaman H, Marques I, Petty D, et al. Associations between anticholinergic medication exposure and adverse health outcomes in older people with frailty: a systematic review and meta-analysis. Drugs Real World Outcomes. 2021;8:431–58.
pubmed: 34164795
pmcid: 8605959
doi: 10.1007/s40801-021-00256-5
Stewart C, Taylor-Rowan M, Soiza RL, Quinn TJ, Loke YK, Myint PK. Anticholinergic burden measures and older people’s falls risk: a systematic prognostic review. Ther Adv Drug Saf. 2021;12:20420986211016644.
pubmed: 34104401
pmcid: 8170331
doi: 10.1177/20420986211016645
Reinold J, Schafer W, Christianson L, Barone-Adesi F, Riedel O, Pisa FE. Anticholinergic burden and fractures: a systematic review with methodological appraisal. Drugs Aging. 2020;37:885–97.
pubmed: 33094444
pmcid: 7704512
doi: 10.1007/s40266-020-00806-6
Egberts A, Moreno-Gonzalez R, Alan H, Ziere G, Mattace-Raso FUS. Anticholinergic drug burden and delirium: a systematic review. J Am Med Dir Assoc. 2021;22(65–73): e4.
Taylor-Rowan M, Edwards S, Noel-Storr AH, McCleery J, Myint PK, Soiza R, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5:CD013540.
pubmed: 34097766
Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018;361: k1315.
pubmed: 29695481
pmcid: 5915701
doi: 10.1136/bmj.k1315
Lupu AM, MacCamy KL, Gannon JM, Brar JS, Chengappa KNR. Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry. 2021;33:80–92.
pubmed: 33878282
Desmarais JE, Beauclair L, Annable L, Bélanger MC, Kolivakis TT, Margolese HC. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4:257–67.
pubmed: 25489477
pmcid: 4257986
doi: 10.1177/2045125314553611
Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41:167–78.
pubmed: 30659492
doi: 10.1007/s11096-019-00784-9
Howland RH. Potential adverse effects of discontinuing psychotropic drugs. Part 1: adrenergic, cholinergic, and histamine drugs. J Psychosoc Nurs Ment Health Serv. 2010;48:11–4.
pubmed: 20795589
de Leon J, Canuso C, White AO, Simpson GM. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Community Psychiatry. 1994;45:606–7.
pubmed: 8088744
Ogino S, Miyamoto S, Tenjin T, Kitajima R, Ojima K, Miyake N, et al. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:78–83.
pubmed: 20828595
doi: 10.1016/j.pnpbp.2010.08.030
Lupu AM, Clinebell K, Gannon JM, Ellison JC, Chengappa KNR. Reducing anticholinergic medication burden in patients with psychotic or bipolar disorders. J Clin Psychiatry. 2017;78:e1270–5.
pubmed: 29178683
doi: 10.4088/JCP.16m11269
Corre KA, Niemann JT, Bessen HA. Extended therapy for acute dystonic reactions. Ann Emerg Med. 1984;13:194–7.
pubmed: 6696308
doi: 10.1016/S0196-0644(84)80613-7
Kowalski JM. Medication-induced dystonic reactions. 2022. https://emedicine.medscape.com/article/814632-overview . Accessed 4 Apr 2023.
Trenaman SC, Bowles SK, Andrew MK, Goralski K. The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. Pharmacol Res Perspect. 2021;9: e00775.
pubmed: 34003603
pmcid: 8130657
doi: 10.1002/prp2.775
Roh E, Cota E, Lee JP, Madievsky R, Eskildsen MA. Polypharmacy in nursing homes. Clin Geriatr Med. 2022;38:653–66.
pubmed: 36210082
doi: 10.1016/j.cger.2022.05.007
Young EH, Pan S, Yap AG, Reveles KR, Bhakta K. Polypharmacy prevalence in older adults seen in United States physician offices from 2009 to 2016. PLoS ONE. 2021;16: e0255642.
pubmed: 34343225
pmcid: 8330900
doi: 10.1371/journal.pone.0255642
2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;2023(71):2052–81.
doi: 10.1111/jgs.18372
Edjolo A, Dartigues JF, Peres K, Proust-Lima C. Heterogeneous long-term trajectories of dependency in older adults: the PAQUID cohort, a population-based study over 22 years. J Gerontol A Biol Sci Med Sci. 2020;75:2396–403.
pubmed: 32115657
doi: 10.1093/gerona/glaa057
Ward LM, Cooper SA, Henderson A, Stanley B, Greenlaw N, Pacitti C, et al. A study on prescriptions contributing to the risk of high anticholinergic burden in adults with intellectual disabilities: retrospective record linkage study. Ann Gen Psychiatry. 2022;21:41.
doi: 10.1186/s12991-022-00418-x
Thayer N, White S, Islam J, Jones W, Kenzie S, Kullu R. Reducing risks associated with medicines and lifestyle in a residential care population with intellectual disabilities: evaluation of a pharmacy review initiative in England. BMJ Open. 2021;11: e046630.
pubmed: 34404698
pmcid: 8372807
doi: 10.1136/bmjopen-2020-046630
Maltais A, Simard M, Vedel I, Sirois C. Changes in polypharmacy and psychotropic medication use after diagnosis of major neurocognitive disorders: a population-based study in Quebec, Canada. Alzheimer Dis Assoc Disord. 2022;36:222–9.
pubmed: 35661072
doi: 10.1097/WAD.0000000000000513
Wang K, Alan J, Page AT, Dimopoulos E, Etherton-Beer C. Anticholinergics and clinical outcomes amongst people with pre-existing dementia: a systematic review. Maturitas. 2021;151:1–14.
pubmed: 34446273
doi: 10.1016/j.maturitas.2021.06.004
Land W, Pinsky D, Salzman C. Abuse and misuse of anticholinergic medications. Hosp Community Psychiatry. 1991;42:580–1.
pubmed: 1677920
Collins TN, Avondoglio JB, Terry LM. Correctional psychopharmacology: pitfalls, challenges, and victories of prescribing in a correctional setting. Int Rev Psychiatry. 2017;29:34–44.
pubmed: 27670976
doi: 10.1080/09540261.2016.1235017